natgillin/translations-raw huggingface dataset:
Liprolog is a replacement insulin, which very similar to the insulin made by the pancreas.
Zdravilo Liprolog je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja trebušna slinavka.
The active substance in Liprolog, insulin lispro, is produced by a method known as ‘ recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin lispro.
Zdravilno učinkovino v zdravilu Liprolog, insulin lispro, proizvajajo z metodo, znano kot „ tehnologija rekombinantne DNK “, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori insulin lispro.
Insulin lispro is very slightly different from human insulin.
Insulin lispro se le malo razlikuje od humanega insulina.
The change means that insulin lispro is absorbed faster by the body than human regular insulin, and can therefore act faster.
Ta majhna razlika omogoča, da telo insulin lispro absorbira hitreje kot običajni humani insulin, zaradi česar je njegovo učinkovanje hitrejše.
Insulin lispro is available as Liprolog in the soluble form, which acts more or less immediately after injection, and as Liprolog Basal in the ‘ protamine suspension’ form, which is absorbed much more slowly so that it works for longer.
Insulin lispro se v zdravilu Liprolog nahaja v topni obliki, ki začne učinkovati bolj ali manj takoj po injiciranju, medtem ko je v zdravilu Liprolog Basal na voljo v obliki „ suspenzije s protaminom “, ki se absorbira veliko počasneje, kar zagotavlja daljše trajanje učinkovanja.
Liprolog Mix is a mixture of these two formulations.
Zdravilo Liprolog Mix je mešanica teh dveh formulacij.
Liprolog was originally studied in eight clinical trials including 2,951 patients with type 1 or type 2 diabetes.
Zdravilo Liprolog je bilo prvotno preučevano v okviru osmih kliničnih preskušanj, v katere je bilo vključenih 2951 bolnikov s sladkorno boleznijo tipa 1 ali tipa 2.
The effectiveness of Liprolog was compared with that of Humulin R (a soluble recombinant DNA human insulin), when they were added to long-acting insulins given once or twice a day.
Učinkovitost zdravila Liprolog so primerjali z učinkovitostjo Humulina R (topnega humanega insulina, pridobljenega z rekombinantno DNK), pri čemer so zdravili dodajali insulinom z dolgotrajnejšim delovanjem, odmerjenim enkrat ali dvakrat dnevno.
The studies measured the level of a substance in the blood called ‘ glycosylated haemoglobin’ (HbA1c), which gives an indication of how well the blood glucose is controlled, and ‘ fasting’ blood glucose levels (measured at least eight hours after eating).
V študijah so merili raven snovi v krvi, imenovane „ glikozilirani hemoglobin “ (HbA1c), ki kaže, kako dobro je glukoza v krvi uravnana, ter ravni glukoze v krvi na tešče (izmerjene vsaj osem ur po zaužitju obroka).
Studies were also done looking at the use of Liprolog in 542 children and adolescents (aged between two and 19 years), and the use of Liprolog in combination with sulphonylureas (antidiabetic medicines taken by mouth).
Opravljene so bile tudi študije, ki so preučevale uporabo zdravila Liprolog pri 542 otrocih in mladostnikih (starih od dveh do 19 let) in uporabo zdravila Liprolog v kombinaciji s sulfonilsečninami (peroralnimi zdravili za sladkorno bolezen).
Liprolog and Humulin R had a similar effect on the control of diabetes, as measured by HbA1c and fasting glucose levels.
Zdravili Liprolog in Humulin R sta imeli podoben učinek na nadzor sladkorne bolezni, ki so ga določili na podlagi izmerjene ravni HbA1c in ravni glukoze na tešče.
Liprolog may cause hypoglycaemia (low blood glucose).
Zdravilo Liprolog lahko povzroči hipoglikemijo (nizko raven glukoze v krvi).
For the full description of all side effects reported with Liprolog, see the Package Leaflet.
Za celoten opis vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Liprolog, glejte navodilo za uporabo.
Liprolog should not be used in people who may be hypersensitive (allergic) to insulin lispro or any of the other ingredients.
Zdravila Liprolog ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) insulin lispro ali katero koli drugo sestavino zdravila.
Liprolog doses might need to be adjusted when given with other medicines that may have an effect on blood glucose levels.
Odmerke zdravila Liprolog bo morda potrebno prilagoditi, če se jemlje sočasno z drugimi zdravili, ki vplivajo na ravni glukoze v krvi.
Liprolog Mix and Liprolog Basal should never be given into a vein.
Zdravil Liprolog Mix in Liprolog Basal se nikoli ne sme vbrizgati v veno.
The Committee for Medicinal Products for Human Use (CHMP) decided that Liprolog’ s benefits are greater than its risks for the treatment of diabetes mellitus.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Liprolog pri zdravljenju sladkorne bolezni večje od z njim povezanih tveganj.
The Committee recommended that Liprolog be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Liprolog odobri dovoljenje za promet.
Other information about Liprolog:
Druge informacije o zdravilu Liprolog:
The European Commission granted marketing authorisations valid throughout the European Union for Liprolog to Eli Lilly Nederland B V. on 1 August 2001.
Evropska komisija je dovoljenje za promet z zdravilom Liprolog, veljavno po vsej Evropski uniji, odobrila družbi Eli Lilly Nederland B. V. dne 1. avgusta 2001.
The marketing authorisation was renewed on 1 August 2006.
Dovoljenje za promet je bilo obnovljeno dne 1. avgusta 2006.
The full EPAR for Liprolog is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Liprolog je na voljo tukaj.
EU Number EU/ 1/ 01/ 195/ 001
Številka EU EU/ 1/ 01/ 195/ 001
Invented name Liprolog
zaščiteno ime Liprolog
Strength 100 U/ ml
jakost 100 i. e. / ml
Pharmaceutical Form Solution for injection
farmacevtska oblika raztopina za injiciranje
Route of Administration Subcutaneous or intravenous use
pot uporabe subkutana ali intravenska uporaba
Packaging vial (glass)
ovojnina viala (steklo)
Content 10 ml (3.5 mg/ ml)
vsebina 10 ml (3, 5 mg/ ml)
Package size 1 vial
velikost pakiranja 1 viala
5 pre-filled pens
5 peresnikov
2 x (5 x 3 ml) cartridges
2 x 5 vložkov
2 x (5 x 3 ml) pre-filled pens
2 x 5 peresnikov
Liprolog Basal
Liprolog BASAL
5 x cartridges
5 vložkov
Liprolog Basal
Liprolog Basal Pen
cartridge (glass)
vložek (steklo) v napolnjenem injekcijskem peresniku
3 ml (3.5 mg/ ml)
5 peresnikov
Liprolog Basal Pen
Liprolog Basal
cartridge (glass) in pre-filled pen
vložek (steklo)
5 pre-filled pens
2 x 5 peresnikov
Liprolog 100 U/ ml, solution for injection in vial
Liprolog 100 i. e. / ml raztopina za injiciranje v viali
When necessary Liprolog can be given soon after meals.
Po potrebi se lahko Zdravilo Liprolog daje tudi kmalu po obrokih.
Liprolog preparations should be given by subcutaneous injection or by continuous subcutaneous infusion pump (see section 4.2) and may, although not recommended, also be given by intramuscular injection.
Pripravke zdravila Liprolog dajemo s subkutano injekcijo ali s kontinuirno subkutano infuzijsko črpalko (glejte poglavje 4. 2), lahko pa tudi z intramuskularno injekcijo, čeprav to ni priporočljivo.
2 Liprolog can be used in conjunction with a longer-acting human insulin or oral sulphonylurea agents, on the advice of a physician.
Po nasvetu zdravnika se lahko zdravilo Liprolog uporabi hkrati s humanim insulinom z dolgotrajnejšim delovanjem ali peroralnimi pripravki s sulfonilsečnino.
3 Insulin requirements may be reduced in the presence of renal impairment.
V prisotnosti ledvične okvare so lahko potrebe po insulinu zmanjšane.
Insulin requirements may be increased during illness or emotional disturbances.
3 Potrebe po insulinu se lahko povečajo v času bolezni ali čustvenih težav.
The physician should be consulted when using other medications in addition to Liprolog.
Pri sočasni uporabi zdravila Liprolog in drugih zdravil se je potrebno posvetovati z zdravnikom.
No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e. g. a patient`s level of diet and exercise.
Pogostnost hipoglikemije ni navedena, hipoglikemija je namreč rezultat tako doze insulina kot drugih faktorjev, kot so bolnikova prehrana in telesna dejavnost.
5 Insulin lispro has a rapid onset of action (approximately 15 minutes), thus allowing it to be given closer to a meal (within zero to 15 minutes of the meal) when compared to regular insulin (30 to 45 minutes before).
Insulin lispro začne delovati hitro (po približno 15 minutah), zato si ga je mogoče dati časovno bliže obroku (0 do 15 minut pred obrokom) v primerjavi z navadnim insulinom (30 do 45 minut pred obrokom).
Humulin R Hypoglycaemic Activity
Humulin R Hipoglikemična Hypoglycaemic aktivnost Activity
6 Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration.
Za insulin lispro je bilo dokazano, da je na molarni osnovi enako močan kot humani insulin, a je njegov učinek hitrejši in bolj kratkotrajen.
7 The solution is contained in type I flint glass vials, sealed with butyl or halobutyl stoppers and secured with aluminium seals.
Raztopina je pakirana v steklene viale iz kremenovega stekla tipa I, zaprte z zamaškom iz butilne ali halobutilne gume in zaščitene z aluminijasto zaporko.
6.6 Special precautions for disposal and other handling
1 x 10 ml Liprolog viala 2 x 10 ml Liprolog viali 5 x (1 x 10 ml) Liprolog viale 7 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
ii) Mixing Liprolog with longer-acting Human Insulins (see section 6.2)
ii) Mešanje zdravila Liprolog s humanimi insulini z dolgotrajnejšim delovanjem (glejte poglavje 6. 2)
1 x 10 ml Liprolog vial 2 x 10 ml Liprolog vials 5 x (1 x 10 ml) Liprolog vials
1 x 10 ml Liprolog viala 2 x 10 ml Liprolog viali 5 x (1 x 10 ml) Liprolog viale
1st August 2001 Date of last renewal:
1. avgust 2001 Datum zadnjega podaljšanja dovoljenja za promet:
1st August 2006
1. avgust 2006
Liprolog 100 U/ ml, solution for injection in cartridge
Liprolog 100 i. e. / ml raztopina za injiciranje v vložku
The faster onset of action compared to soluble human insulin is maintained regardless of injection site As with all insulin preparations, the duration of action of Liprolog is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Kakor velja za vse pripravke insulina, je trajanje delovanja zdravila Liprolog odvisno od odmerka, mesta injiciranja, prekrvitve tkiva, temperature in telesne dejavnosti.
11 Liprolog can be used in conjunction with a longer-acting human insulin or oral sulphonylurea agents, on the advice of a physician.
Po nasvetu zdravnika se lahko zdravilo Liprolog uporabi hkrati s humanim insulinom z dolgotrajnejšim delovanjem ali peroralnimi pripravki s sulfonilsečnino.
12 Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Potrebe po insulinu so lahko zmanjšane tudi pri bolnikih z jetrno okvaro zaradi zmanjšane zmogljivosti za glukoneogenezo in zmanjšane razgradnje insulina, vendar pa lahko pri bolnikih s kronično jetrno okvaro povečanje rezistence na insulin vodi v povečano potrebo po insulinu.
Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet.
11 Odmerjanje je morda treba prilagoditi tudi, če bolnik poveča telesno dejavnost ali spremeni običajni način prehrane.
13 4.8 Undesirable effects
4. 8 Neželeni učinki
Local allergy in patients is common (1/ 100 to < 1/ 10).
12 Lokalna alergijska reakcija je pogost (> 1/ 100, < 1/ 10) neželen učinek.
14 Insulin lispro has a rapid onset of action (approximately 15 minutes), thus allowing it to be given closer to a meal (within zero to 15 minutes of the meal) when compared to regular insulin (30 to 45 minutes before).
Insulin lispro začne delovati hitro (po približno 15 minutah), zato si ga je mogoče dati časovno bliže obroku (0 do 15 minut pred obrokom) v primerjavi z navadnim insulinom (30 do 45 minut pred obrokom).
15 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
Ledvična ali jetrna okvara ne vpliva na glukodinamični odziv na insulin lispro.
16 Store in a refrigerator (2°C - 8°C).
Shranjujte v hladilniku (2 °C - 8 °C).
5 x 3 ml Liprolog cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog cartridges for a 3 ml pen
5 x 3 ml Liprolog vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog vložki za 3 ml injekcijski peresnik
Instructions for use and handling Liprolog cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Navodila za pripravo in ravnanje z zdravilom Vložke zdravila Liprolog uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Date of first authorisation:
16 Datum pridobitve dovoljenja za promet:
Liprolog Mix25 100 U/ ml suspension for injection in cartridge
Liprolog Mix25 100 i. e. / ml suspenzija za injiciranje v vložku
Liprolog Mix 25 consists of 25% insulin lispro solution and 75% insulin lispro protamine suspension.
Zdravilo Liprolog Mix25 vsebuje 25% raztopine insulina lispro in 75% suspenzije insulina lispro - protamin.
The duration of action of the insulin lispro protamine suspension (Basal) component of Liprolog Mix25 is similar to that of a basal insulin NPH.
Trajanje delovanja sestavine zdravila Liprolog Mix25 suspenzije insulina lispro- protamin (Basal) je podobno kot pri bazalnem insulinu (NPH).
19 Hypersensitivity to insulin lispro or to any of the excipients.
Preobčutljivost za insulin lispro ali katerokoli pomožno snov.
Hypoglycaemia.
18 Hipoglikemija.
The physician should be consulted when using other medications in addition to Liprolog Mix25.
Pri sočasni uporabi zdravila Liprolog Mix25 in drugih zdravil se je potrebno posvetovati z zdravnikom.
20 Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/ newborn.
19 Podatki zbrani na velikem številu nosečnic ne kažejo na možnost škodljivih vplivov insulina lispro na nosečnost ali zdravje zarodka/ novorojenca.
21 If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously.
20 Če je bolnik komatozen, damo glukagon intramuskularno ali subkutano.
Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with Liprolog Mix25 compared to human insulin mixture 30/ 70.
Klinična preskušanja pri bolnikih z diabetesom tipa 1 in 2 so pokazala, da je pri uporabi zdravila Liprolog Mix25 v primerjavi z mešanico humanega insulina 30/ 70 manj postprandialnih hiperglikemij.
Hypoglycaemic activity Liprolog Mix25 Liprolog Basal
Hipoglikemična aktivnost
22 The above representation reflects the relative amount of glucose over time required to maintain the subject's whole blood glucose concentrations near fasting levels and is an indicator of the effect of these insulins on glucose metabolism over time.
21 Zgornji diagram ponazarja časovni potek učinkov obeh insulinov na presnovo glukoze, ki je potrebna za vzdrževanje koncentracije glukoze v polni krvi blizu ravni na tešče.
In two 8-month open label crossover studies, type 2 diabetes patients who were either new to insulin therapy or already using one or two injections of insulin, received 4 months of treatment with Liprolog Mix25 (used twice daily with metformin) and insulin glargine (used once daily with metformin) in a randomised sequence.
V dveh 8- mesečnih, odprtih, navzkrižnih študijah, so bolniki z diabetesom 2, ki so bodisi začeli zdravljenje z insulinom ali pa so že uporabljali eno ali dve injekciji insulina, 4 mesece v naključnem zaporedju prejemali zdravljenje z zdravilom Liprolog Mix25 (dvakrat na dan z metforminom) in insulinom glargin (enkrat na dan z metforminom).
Incidence of hypoglycaemia at endpoint Bodyweight gain2 1 from baseline to end of Liprolog Mix25 treatment 2
Končna incidenca hipoglikemije Zvišanje telesne mase2 1
in patients randomised to Liprolog Mix25 during
od osnovne vrednosti do konca zdravljenja z 2
the first crossover period
zdravilom Liprolog Mix25
Insulin lispro did not induce fertility impairment, embryotoxicity or teratogenicity in animal studies.
22 Insulin lispro v študijah na živalih ni povzročil zmanjšane plodnosti, embriotoksičnosti ali teratogenosti.
2 x (5 x 3 ml) Liprolog Mix25 cartridges for a 3 ml pen.
5 x 3 ml Liprolog Mix25 vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog Mix25 vložki za 3 ml injekcijski peresnik
Instructions for use and handling Liprolog Mix25 cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Navodila za pripravo in ravnanje z zdravilom Vložke zdravila Liprolog Mix25 uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Cartridges containing Liprolog Mix25 should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky.
23 Vložke, ki vsebujejo zdravilo Liprolog Mix25, je treba tik pred uporabo desetkrat zavrteti med dlanmi rok in desetkrat obrniti za 180°, da ponovno suspendirate insulin, dokler ni enakomerno motnega ali mlečnega videza.
Cartridges contain a
Če ni takega videza, ponavljajte zgoraj opisani postopek, dokler sestavine niso zmešane.
24 small glass bead to assist mixing.
Vložki vsebujejo majhno stekleno kroglico, ki je v pomoč pri mešanju.
5 x 3 ml Liprolog Mix25 cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Mix25 cartridges for a 3 ml pen
5 x 3 ml Liprolog Mix25 vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog Mix25 vložki za 3 ml injekcijski peresnik
Liprolog Mix50 100 U/ ml suspension for injection in cartridge
Liprolog Mix50 100 i. e. / ml suspenzija za injiciranje v vložku
Liprolog Mix50 consists of 50% insulin lispro solution and 50% insulin lispro protamine suspension.
Zdravilo Liprolog Mix50 vsebuje 50% raztopine insulina lispro in 50% suspenzije insulina lispro - protamin.
The duration of action of the insulin lispro protamine suspension (Basal) component of Liprolog Mix50 is similar to that of a basal insulin (NPH).
Trajanje delovanja sestavine zdravila Liprolog Mix50 suspenzije insulina lispro- protamin (Basal) je podobno kot pri bazalnem insulinu (NPH).
26 Hypoglycaemia.
26 Hipoglikemija.
The physician should be consulted when using other medications in addition to Liprolog Mix50.
Pri sočasni uporabi zdravila Liprolog Mix50 in drugih zdravil se je potrebno posvetovati z zdravnikom.
27 Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/ newborn.
27 Podatki zbrani na velikem številu nosečnic ne kažejo na možnost škodljivih vplivov insulina lispro na nosečnost ali zdravje zarodka/ novorojenca.
28 If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously.
28 Če je bolnik komatozen, damo glukagon intramuskularno ali subkutano.
Liprolog Liprolog Basall
Liprolog Mix50 Basal
29 The glucodynamic response to insulin lispro is not affected by renal or hepatic function impairment.
Ledvična ali jetrna okvara ne vpliva na glukodinamični odziv na insulin lispro.
Insulin lispro has been shown to be equipotent to human insulin on a molar basis but its effect is more rapid and of a shorter duration.
29 Za insulin lispro je bilo dokazano, da je na molarni osnovi enako močan kot humani insulin, a je njegov učinek hitrejši in bolj kratkotrajen.
30 After insertion of the cartridge in a pen, the suspension should be used in 28 days when stored below 30°C.
Po vstavitvi vložka v injekcijski peresnik je treba suspenzijo porabiti v 28 dneh, če je shranjena pri temperaturi do 30 °C.
2 x (5 x 3 ml) Liprolog Mix50 cartridges for a 3 ml pen.
5 x 3 ml Liprolog Mix50 vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog Mix50 vložki za 3 ml injekcijski peresnik
Instructions for use and handling Liprolog Mix50 cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Navodila za pripravo in ravnanje z zdravilom Vložke zdravila Liprolog Mix50 uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Liprolog Mix50 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Vložki zdravila Liprolog Mix50 so oblikovani tako, da onemogočajo mešanje kakih drugih insulinov v vložku.
5 x 3 ml Liprolog Mix50 cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Mix50 cartridges for a 3 ml pen
5 x 3 ml Liprolog Mix50 vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog Mix50 vložki za 3 ml injekcijski peresnik
Liprolog Basal 100 U/ ml suspension for injection in cartridge
Liprolog Basal 100 i. e. / ml suspenzija za injiciranje v vložku
Liprolog Basal consists of insulin lispro protamine suspension.
Zdravilo Liprolog Basal vsebuje suspenzijo insulina lispro- protamin.
Liprolog Basal may be used alone, in combination with oral agents, or mixed with insulin lispro solution.
Zdravilo Liprolog Basal se lahko uporablja samostojno, v kombinaciji s peroralnimi zdravili ali se meša z raztopino zdravila insulin lispro.
In intensive insulin therapy Liprolog Basal may be used as basal insulin (evening and/ or morning injection) with fast-acting insulin given at meals.
Pri intenzivni insulinski terapiji se zdravilo Liprolog Basal lahko uporablja kot osnovni insulin (injiciranje zvečer in/ ali zjutraj) s hitro delujočimi insulini, ki jih dajemo pri obrokih.
Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen (see section 6.6).
Zdravilo subkutano injiciramo v nadlakti, stegna, zadnjico ali trebuh (glejte poglavje 6. 6).
The physician should be consulted when using other medications in addition to Liprolog Basal.
Pri sočasni uporabi zdravila Liprolog Basal in drugih zdravil se je potrebno posvetovati z zdravnikom.
34 It is essential to maintain good control of the insulin-treated (insulin-dependent or gestational diabetes) patient throughout pregnancy.
34 trimesečju nosečnosti in se povečajo v drugem in tretjem trimesečju.
35 Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
35 Morda bosta potrebna vzdrževan vnos ogljikovih hidratov in opazovanje, ker se lahko hipoglikemija po navideznem kliničnem okrevanju ponovno pojavi.
Protamine sulphate m-cresol [1.76 mg/ ml] 36 Phenol [0.80 mg/ ml] Glycerol Dibasic sodium phosphate.7H2O Zinc oxide Water for injections Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.
Protamin sulfat 36 Metakrezol [1, 76 mg/ ml] Fenol [0, 80 mg/ ml] Glicerol Natrijev hidrogenfosfat heptahidrat Cinkov oksid Voda za injekcije Za uravnavanje pH na 7, 0- 7, 8 sta morda bila uporabljena klorovodikova kislina in natrijev hidroksid.
5 x 3 ml Liprolog Basal cartridges for a 3 ml pen 2 x (5 x 3 ml) Liprolog Basal cartridges for a 3 ml pen
5 x 3 ml Liprolog Basal vložki za 3 ml injekcijski peresnik 2 x (5 x 3 ml) Liprolog Basal vložki za 3 ml injekcijski peresnik
Instructions for use and handling Liprolog Basal cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Navodila za pripravo in ravnanje z zdravilom Vložke zdravila Liprolog Basal uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Liprolog Basal cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Vložki zdravila Liprolog Basal so oblikovani tako, da onemogočajo mešanje kakih drugih insulinov v vložku.
37 The following is a general description.
37 V nadaljevanju je podan splošen opis postopka.
Liprolog Pen 100 U/ ml, solution for injection
Liprolog Pen 100 i. e. / ml raztopina za injiciranje